SCHEMBL23937987

SCHEMBL23937987

Cc1cnc2c(c1)CCC2O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
P2RX7 Q99572 2/20 0.33
UGT2B17 O75795 2/20 0.33
CCR1 P32246 1/20 0.31
CCR5 P51681 1/20 0.31
CCR8 P51685 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31
GFRA3 O60609 1/20 0.31
RET P07949 1/20 0.31
FNTA P49354 1/20 0.31
FNTB P49356 1/20 0.31
EPAS1 Q99814 1/20 0.31
CXCR4 P61073 1/20 0.31
CHRNA7 P36544 1/20 0.31
OPRL1 P41146 2/20 0.31
KCNH2 Q12809 2/20 0.31
ADRA2A P08913 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10286348 0.89 UGT2B17 (0.41) DRD2DRD1P2RX7UGT2B17FNTA
SCHEMBL14884996 0.89 UGT2B17 (0.41) DRD2DRD1P2RX7UGT2B17FNTA
SCHEMBL10238793 0.79 DRD2 (0.34) DRD2DRD1CCR1CCR5CCR8
SCHEMBL12696395 0.78 EPAS1 (0.34) GFRA3RETEPAS1
SCHEMBL568654 0.78 TRPM5 (0.36) GFRA3RETFNTAFNTBEPAS1
SCHEMBL30849377 0.78 EPAS1 (0.40) GFRA3RETEPAS1OPRL1
SCHEMBL24729873 0.78 GFRA3 (0.31) GFRA3RETEPAS1
SCHEMBL6845123 0.78 NOS3 (0.35) DRD2DRD1CCR1CCR5CCR8
SCHEMBL14616897 0.78 FNTA (0.33) GFRA3RETFNTAFNTB
SCHEMBL12983640 0.78 NOS3 (0.35) DRD2DRD1CCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors VALO HEALTH, INC. (US) 2022-12-13 US disclosed
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS VALO EARLY DISCOVERY, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524966-B1 Carboxamides as ubiquitin-specific protease inhibitors USP28, USP25, USP24 DRD2 4467/4885DRD1 4069/4885P2RX7 3760/4885
US-20210323975-A1 CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS USP28, USP25, USP24 DRD2 4467/4885DRD1 4069/4885P2RX7 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.